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from €1132 (lower bound) to €1199 (upper bound). The
mean cost of atenolol per patient was €366. The mean
costs of the cardiovascular events were respectively €1969
and €2261 for losartan and atenolol groups. Therefore,
the total mean cost per patient ranged from €3101 to
€3169 for the losartan group and was estimated €2627
for the atenolol group. CONCLUSION: The annual
incremental cost for each patient treated with losartan
ranged from €99 to €113. This additional cost is associ-
ated with a signiﬁcant reduction in cardiovascular mor-
bidity and mortality (especially stroke).
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OBJECTIVE: To determine differences in costs in hyper-
tensive, NSAID-treated patients whose hypertension is
controlled or uncontrolled. METHODS: Claims data
from Careﬁrst BCBS were used to compare the mean
annualized total costs between groups. Patients were
included if they had a medical claim for hypertension
(ICD-9 of 401.xx-404.xx) between February 1, 1999 and
July 31, 2001 and the ﬁrst claim for an NSAID (index
date) between August 1, 1999 and July 31, 2001. NSAID
usage included non-speciﬁc NSAIDs and COX-2 speciﬁc
inhibitors. Uncontrolled hypertension was deﬁned as one
of the following occurring within 6 weeks following the
index date: 1) 1 hypertension related hospitalizations,
emergency room visit or outpatient visit or 2) a switch to
or addition of another antihypertensive drug. All billed
charges between the index date and end of the study
period were used to calculate mean annualized health care
costs. A logistic model was used to assess the determi-
nants of hypertension control. RESULTS: A total of 9805
patients were included. The difference in unadjusted
annualized mean total cost for controlled ($6774; N =
7282) and uncontrolled patients ($9342; N = 2523) was
$2568 (p < 0.0001). Mean annualized costs were $4856
(pre-index) and $4732 (post-index) for the controlled
group and $5038 (pre-index) and $5394 (post-index) for
the uncontrolled group (signiﬁcant at p < 0.001). Differ-
ences were consistently greater for hypertension related
than non-hypertension related costs. Patients were 1%,
and 28% less likely to be controlled, per year of increase
in age or they had diabetes, respectively. CONCLUSION:
Patients using an NSAID, with uncontrolled hypertension
incur incremental medical costs of approximately $2500
annually when compared to those with controlled hyper-
tension. Older or diabetic patients are more likely to have
uncontrolled hypertension. Further research is recom-
mended at the drug level, to determine if particular
NSAIDS, including COX-2 speciﬁc inhibitors, are associ-
ated with a greater likelihood of uncontrolled hyperten-
sion and if differences in total treatment costs exist by
drug.
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OBJECTIVES: The Joint National Committee for the Pre-
vention, Detection and Treatment of High Blood Pressure
(JNC-VI) has published guidelines recommending thi-
azide diuretics (TZDs) or beta-blockers for the initial
medication management of hypertension. Recent studies
have corroborated these guidelines by demonstrating no
difference in morbidity and mortality between chlorthali-
done, amlodapine, and lisinopril in the treatment of
hypertension. Thus, selection between these agents repre-
sents an issue of cost with similar outcomes. Hamilton
and Clause have reported the prevalence of these agents
for the treatment of hypertension in a sample of NYS
Medicaid recipients, and observed variances from 
treatment guidelines. Using their results and the NYS
Medicaid prescription database, differences in costs for
single-agent treatments were assessed. METHODS: Pre-
scription utilization data were abstracted from the NYS
Medicaid claims database for a sample of 2689 beneﬁ-
ciaries with hypertension in 1999. Three groups were
identiﬁed: a) 267 receiving only a TZD; b) 964 receiving
only a calcium antagonist (CA); and c) 941 receiving
either an ACEI or an ARB. Medicaid costs and days
supply were queried for the following drug classes: a)
ACEI; b) ARB; c) CA; and d) TZDs. Average cost-per-day
were calculated for each category. Results were then
adjusted for previously observed variances from treat-
ment guidelines. RESULTS: Cost/day for each group were
as follows: a) $0.18/day for TZDs; b) $1.58/day for CA;
and c) $1.18/day for ACEI or ARBs. Compared to TZD,
the excess costs for inappropriate CA therapy were esti-
mated at $1.40/day or $511 per patient per year. Total
potential patients beneﬁting from appropriate therapy
were estimated from national trends. With 328,578
hypertensive NYS Medicaid patients, inappropriate ther-
apies could account for more than $4.2 million in excess
expenditures. CONCLUSION: There is potential for 
signiﬁcant annual savings to NYS Medicaid through
improved application of JNC-VI guidelines to the initial
treatment of hypertension.
